Audit 315080

FY End
2023-12-31
Total Expended
$2.79M
Findings
8
Programs
6
Year: 2023 Accepted: 2024-07-15

Organization Exclusion Status:

Checking exclusion status...

Findings

ID Ref Severity Repeat Requirement
478396 2023-002 - - C
478397 2023-002 - - C
478398 2023-003 Significant Deficiency - C
478399 2023-003 Significant Deficiency - C
1054838 2023-002 - - C
1054839 2023-002 - - C
1054840 2023-003 Significant Deficiency - C
1054841 2023-003 Significant Deficiency - C

Programs

ALN Program Spent Major Findings
93.855 Allergy, Immunology and Transplantation Research $590,732 Yes 0
93.172 Human Genome Research $475,864 Yes 2
93.396 Cancer Biology Research $184,601 Yes 0
93.859 Biomedical Research and Research Training $169,634 Yes 0
47.074 Biological Sciences $167,982 Yes 0
47.049 Mathematical and Physical Sciences $115,059 Yes 0

Contacts

Name Title Type
GX1TUDQ8F9M5 Jackie McCarter Auditee
3864188085 Jeff Fox Auditor
No contacts on file

Notes to SEFA

Title: Note 3—Noncash awards Accounting Policies: The accompanying schedule of expenditures of federal awards (the “Schedule”) includes the federal award activity of the Foundation for Applied Molecular Evolution, Inc. (the “Foundation”) under programs of the federal government for the year ended December 31, 2023. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations (CFR) Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (“Uniform Guidance”). Because the Schedule presents only a selected portion of the operations of the Foundation, it is not intended to and does not present the financial position, changes in net assets, or cash flows of the Foundation. De Minimis Rate Used: N Rate Explanation: The Foundation expended indirect costs using a multiple allocation base method and did not elect to use the 10% de minimis cost rate allowed under the Uniform Guidance. The Foundation did not receive noncash federal awards during the year ended December 31, 2023.
Title: Note 4—Contingencies Accounting Policies: The accompanying schedule of expenditures of federal awards (the “Schedule”) includes the federal award activity of the Foundation for Applied Molecular Evolution, Inc. (the “Foundation”) under programs of the federal government for the year ended December 31, 2023. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations (CFR) Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (“Uniform Guidance”). Because the Schedule presents only a selected portion of the operations of the Foundation, it is not intended to and does not present the financial position, changes in net assets, or cash flows of the Foundation. De Minimis Rate Used: N Rate Explanation: The Foundation expended indirect costs using a multiple allocation base method and did not elect to use the 10% de minimis cost rate allowed under the Uniform Guidance. These programs are subject to financial and compliance audits by grantor agencies. The amount, if any, of expenditures that may be disallowed by the grantor agencies cannot be determined at this time, although the Foundation expects such amounts, if any, to be immaterial.

Finding Details

Finding 2023-002 – Noncompliance with Cash Management Requirement – Human Genome Research - Enzyme Synthesis of RNA – 93.172 Criteria: Reimbursement requests and related draws should be made for allocable, allowable and reasonable costs that have already been incurred or paid. Condition: During the audit, we noted an instance of grant funding being drawn in excess of allocable, allowable expenditures incurred to the date of the draw. Such allocable, allowable costs were incurred and paid over the subsequent three months which was within the grant term and the fiscal year ended December 31, 2023. Cause: The former grant administrator was anticipating additional allocable, allowable expenditures in the coming month(s). Effect: Financial statements could be materially incorrect. Recommendation: The Foundation should ensure that grant funding only be submitted for reimbursement and cash draws once an expenditure has been made, regardless of anticipated expenditures. Management’s Response: We agree with the finding and will implement procedures to ensure grant funding is drawn based on allocable, allowable expenditures incurred to date.
Finding 2023-002 – Noncompliance with Cash Management Requirement – Human Genome Research - Enzyme Synthesis of RNA – 93.172 Criteria: Reimbursement requests and related draws should be made for allocable, allowable and reasonable costs that have already been incurred or paid. Condition: During the audit, we noted an instance of grant funding being drawn in excess of allocable, allowable expenditures incurred to the date of the draw. Such allocable, allowable costs were incurred and paid over the subsequent three months which was within the grant term and the fiscal year ended December 31, 2023. Cause: The former grant administrator was anticipating additional allocable, allowable expenditures in the coming month(s). Effect: Financial statements could be materially incorrect. Recommendation: The Foundation should ensure that grant funding only be submitted for reimbursement and cash draws once an expenditure has been made, regardless of anticipated expenditures. Management’s Response: We agree with the finding and will implement procedures to ensure grant funding is drawn based on allocable, allowable expenditures incurred to date.
Finding 2023-003 – Significant Deficiency over Internal Controls Related to Cash Management Compliance - Human Genome Research - Enzyme Synthesis of RNA – 93.172 Criteria: The Foundation is responsible for establishing and properly implementing controls over compliance with the grant requirements regarding cash management to ensure that reimbursement requests and related draws are made for allocable, allowable and reasonable costs that have already been incurred or paid. Condition: During the audit, we noted insufficient evidence of the performance of controls related to the timing of draws in relation to the costs incurred to date. Cause: The former grant administrator was responsible for all aspects of grant management, without review by another member of management. Effect: The Foundation was not able to ensure that internal controls were implemented or operating effectively. Recommendation: The Foundation should strengthen its controls related to the cash draw processes to ensure that grant funding only be submitted for reimbursement and cash draws once an expenditure has been made, regardless of anticipated expenditures. Management’s Response: We agree with the finding and will implement procedures to ensure internal controls over grant funding draws is based on allocable, allowable expenditures incurred to date.
Finding 2023-003 – Significant Deficiency over Internal Controls Related to Cash Management Compliance - Human Genome Research - Enzyme Synthesis of RNA – 93.172 Criteria: The Foundation is responsible for establishing and properly implementing controls over compliance with the grant requirements regarding cash management to ensure that reimbursement requests and related draws are made for allocable, allowable and reasonable costs that have already been incurred or paid. Condition: During the audit, we noted insufficient evidence of the performance of controls related to the timing of draws in relation to the costs incurred to date. Cause: The former grant administrator was responsible for all aspects of grant management, without review by another member of management. Effect: The Foundation was not able to ensure that internal controls were implemented or operating effectively. Recommendation: The Foundation should strengthen its controls related to the cash draw processes to ensure that grant funding only be submitted for reimbursement and cash draws once an expenditure has been made, regardless of anticipated expenditures. Management’s Response: We agree with the finding and will implement procedures to ensure internal controls over grant funding draws is based on allocable, allowable expenditures incurred to date.
Finding 2023-002 – Noncompliance with Cash Management Requirement – Human Genome Research - Enzyme Synthesis of RNA – 93.172 Criteria: Reimbursement requests and related draws should be made for allocable, allowable and reasonable costs that have already been incurred or paid. Condition: During the audit, we noted an instance of grant funding being drawn in excess of allocable, allowable expenditures incurred to the date of the draw. Such allocable, allowable costs were incurred and paid over the subsequent three months which was within the grant term and the fiscal year ended December 31, 2023. Cause: The former grant administrator was anticipating additional allocable, allowable expenditures in the coming month(s). Effect: Financial statements could be materially incorrect. Recommendation: The Foundation should ensure that grant funding only be submitted for reimbursement and cash draws once an expenditure has been made, regardless of anticipated expenditures. Management’s Response: We agree with the finding and will implement procedures to ensure grant funding is drawn based on allocable, allowable expenditures incurred to date.
Finding 2023-002 – Noncompliance with Cash Management Requirement – Human Genome Research - Enzyme Synthesis of RNA – 93.172 Criteria: Reimbursement requests and related draws should be made for allocable, allowable and reasonable costs that have already been incurred or paid. Condition: During the audit, we noted an instance of grant funding being drawn in excess of allocable, allowable expenditures incurred to the date of the draw. Such allocable, allowable costs were incurred and paid over the subsequent three months which was within the grant term and the fiscal year ended December 31, 2023. Cause: The former grant administrator was anticipating additional allocable, allowable expenditures in the coming month(s). Effect: Financial statements could be materially incorrect. Recommendation: The Foundation should ensure that grant funding only be submitted for reimbursement and cash draws once an expenditure has been made, regardless of anticipated expenditures. Management’s Response: We agree with the finding and will implement procedures to ensure grant funding is drawn based on allocable, allowable expenditures incurred to date.
Finding 2023-003 – Significant Deficiency over Internal Controls Related to Cash Management Compliance - Human Genome Research - Enzyme Synthesis of RNA – 93.172 Criteria: The Foundation is responsible for establishing and properly implementing controls over compliance with the grant requirements regarding cash management to ensure that reimbursement requests and related draws are made for allocable, allowable and reasonable costs that have already been incurred or paid. Condition: During the audit, we noted insufficient evidence of the performance of controls related to the timing of draws in relation to the costs incurred to date. Cause: The former grant administrator was responsible for all aspects of grant management, without review by another member of management. Effect: The Foundation was not able to ensure that internal controls were implemented or operating effectively. Recommendation: The Foundation should strengthen its controls related to the cash draw processes to ensure that grant funding only be submitted for reimbursement and cash draws once an expenditure has been made, regardless of anticipated expenditures. Management’s Response: We agree with the finding and will implement procedures to ensure internal controls over grant funding draws is based on allocable, allowable expenditures incurred to date.
Finding 2023-003 – Significant Deficiency over Internal Controls Related to Cash Management Compliance - Human Genome Research - Enzyme Synthesis of RNA – 93.172 Criteria: The Foundation is responsible for establishing and properly implementing controls over compliance with the grant requirements regarding cash management to ensure that reimbursement requests and related draws are made for allocable, allowable and reasonable costs that have already been incurred or paid. Condition: During the audit, we noted insufficient evidence of the performance of controls related to the timing of draws in relation to the costs incurred to date. Cause: The former grant administrator was responsible for all aspects of grant management, without review by another member of management. Effect: The Foundation was not able to ensure that internal controls were implemented or operating effectively. Recommendation: The Foundation should strengthen its controls related to the cash draw processes to ensure that grant funding only be submitted for reimbursement and cash draws once an expenditure has been made, regardless of anticipated expenditures. Management’s Response: We agree with the finding and will implement procedures to ensure internal controls over grant funding draws is based on allocable, allowable expenditures incurred to date.